LBSP Favicon

MIMETAS Introduces OrganoPlate UniFlow at SLAS 2025

Leiden, Netherlands – January 28, 2025 – MIMETAS, a leader in human disease modeling, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. The platform debuts at SLAS 2025, expanding MIMETAS’ portfolio of advanced tissue models.

Improving Drug Discovery with Natural Flow Conditions

OrganoPlate UF enables physiologically relevant tissue models by using unidirectional, gravity-driven flow, removing the need for external pumps. This approach simplifies operation while maintaining biological accuracy. With support for up to 512 chips in a single setup, researchers can conduct large-scale studies efficiently.

Features of OrganoPlate UF

• Unidirectional flow: Better replicates blood circulation, making it suitable for cardiovascular, oncology, and immunology research.
• Pump-free, gravity-driven design: Reduces complexity while maintaining conditions similar to the human body.
• Compatible with standard lab equipment: Works with existing liquid handling and imaging systems for efficient, high-throughput analysis.
• Supports long-term studies: Designed for extended culture of complex tissues, including those for chronic disease research.

Expanding Research Possibilities

“For over a decade, the MIMETAS OrganoPlate has been used worldwide to study human disease,” said Bas Trietsch, MIMETAS co-founder. “With UniFlow, we now offer unidirectional flow that closely mimics natural circulation while keeping our system easy to use.”
OrganoPlate UF is already integrated into MIMETAS’ liver, lung, brain, vasculature, and tumor models, supporting research in metabolic, cardiovascular, immunological, and cancer studies. The platform is now available as part of MIMETAS’ research services.

About MIMETAS
MIMETAS (Leiden, Netherlands) develops human-relevant disease models for drug discovery and development. The OrganoPlate® platform powers research for leading pharmaceutical companies worldwide. Founded in 2013, MIMETAS operates in Europe, Asia, and the USA. The company is based at Leiden Bio Science Park, a leading hub for life sciences innovation in the Netherlands.

Related posts

VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.

Key Region Leiden launch

Key Region Leiden launch

𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝘁𝘂𝗿𝗻 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗶𝗻𝘁𝗼 𝗿𝗲𝗮𝗹 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀, 𝗳𝗮𝘀𝘁𝗲𝗿, 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝗮𝗻𝗱 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿? That’s the question Key Region Leiden is working to answer. Launched on July 7 at Leiden...

Vuurvliegen tijdens Dutch Bio Science Week

Vuurvliegen tijdens Dutch Bio Science Week

Peter Lindenburg winnaar VUURVLIEGEN tijdens Dutch Bio Science Week Den Haag, 4 juli 2025 – Bijna 130 leerlingen van vier basisscholen uit de Leidse regio hebben onderzoeker...